Inhibrx Biosciences (INBX) to Release Quarterly Earnings on Monday

Inhibrx Biosciences (NASDAQ:INBX) is projected to post its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Inhibrx Biosciences to post earnings of ($2.08) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 5:00 PM ET.

Inhibrx Biosciences Stock Down 2.1%

Inhibrx Biosciences stock opened at $69.18 on Monday. The company has a market capitalization of $1.01 billion, a PE ratio of -6.90 and a beta of 1.50. The company has a debt-to-equity ratio of 2.71, a quick ratio of 4.49 and a current ratio of 4.49. Inhibrx Biosciences has a fifty-two week low of $10.81 and a fifty-two week high of $94.57. The firm has a 50 day moving average price of $77.08 and a 200 day moving average price of $63.07.

Wall Street Analyst Weigh In

Several research analysts have recently commented on INBX shares. Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Inhibrx Biosciences currently has an average rating of “Reduce”.

Institutional Investors Weigh In On Inhibrx Biosciences

A number of hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in Inhibrx Biosciences in the 1st quarter valued at approximately $27,000. Persistent Asset Partners Ltd purchased a new stake in shares of Inhibrx Biosciences during the fourth quarter worth $27,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Inhibrx Biosciences during the third quarter worth $40,000. BNP Paribas Financial Markets raised its stake in shares of Inhibrx Biosciences by 71.9% in the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after acquiring an additional 789 shares in the last quarter. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Inhibrx Biosciences in the fourth quarter valued at $66,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.